Patents by Inventor Jianliang Lu
Jianliang Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12238220Abstract: A blockchain-based workflow node certification method includes a certification party establishing a general workflow template. The general workflow template includes a plurality of workflow nodes each having an audit attribute for indicating whether the workflow node needs to be certified. The certification party establishes a general data template based on the general workflow template, and the general data template and the general workflow template are instantiated. A current workflow node is acquired in the instantiated general workflow template, and whether the current workflow node needs to be certified-is determined, based on the audit attribute. Certification, if needed, is performed by a centralized certification party, and users can create and modify transaction processes as needed to meet the needs of changeable transactions. By combining central certification with blockchain certification deposition, the security of workflow node process implementation and the privacy of specific data are ensured.Type: GrantFiled: October 14, 2020Date of Patent: February 25, 2025Assignee: Shanghai NanoJClean Technology Co., Ltd.Inventors: Duanxin Lu, Qiangle Geng, Bangya Ma, Jianliang Gu
-
Publication number: 20250051345Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder. ADHD, Phelan-Mc-Dermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease. Brugada Syndrome. Short QT syndrome, or early repolarization syndrome.Type: ApplicationFiled: December 12, 2022Publication date: February 13, 2025Inventors: Simon Krautwald, Jianliang Lu, James Anthony Neef, Hye-Yeon Park, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
-
Publication number: 20240331144Abstract: A novel medical image generation approach synthesizes thin-cut computerized tomography (CT) images from thick-cut CT ones as inputs. First thick-cut CT images are obtained by maximizing the pixel-wise intensity of five or more than five continuous thin-cut ones after image registration. Second, the obtained thick-cut CT images are fed into a generator block which adopts an encoder-decoder architecture, where each thick-cut image is encoded into low-dimensional embedding space before decoding into multiple thin-cut ones. Third, a discriminator focuses on distinguishing original real thin-cut images from synthetic thin-cut images. An adversarial mechanism between the generator and discriminator causes the discriminator's output to provide an effective gradient update of the network parameters for the generator to increasingly improve the generator's ability to synthesize higher-quality thin-cut images and in turn promotes the discriminator's discriminating capability.Type: ApplicationFiled: July 18, 2022Publication date: October 3, 2024Applicants: Versitech Limited, The Education University of Hong KongInventors: Man Fung YUEN, Gilbert Chiu Sing LUI, Jianliang LU, Keith Wan Hang CHIU, Wai Kay Walter SETO, Philip Leung Ho YU
-
Publication number: 20240312009Abstract: A three dimensional classification system for recognizing cross-sectional images automatically contains a processor that executes: (1) rescaling of a plurality of cross-sectional images; and feeding the rescaled plurality of cross-sectional images into two branches; (2) feeding the rescaled plurality of cross-sectional images into a first branch for performing a plurality of convolutions on the rescaled plurality of cross-sectional images directly to learn features for distinguishing phases; (3) feeding the rescaled plurality of cross-sectional images into a second branch for reducing resolution, and then performing a plurality of convolutions on the reduced resolution plurality of cross-sectional images to learn features for distinguishing phases; and (4) concatenating convolutional output channels from the two branches to fuse global and local features, on which two fully-connected layers are stacked as a classifier to recognize cross-sectional volumetric images accurately and quickly.Type: ApplicationFiled: July 6, 2023Publication date: September 19, 2024Applicants: Versitech Limited, The Education University of Hong KongInventors: Keith Wan Hang CHIU, Wai Kay Walter SETO, Gilbert Chiu Sing LUI, Jianliang LU, Man Fung YUEN, Philip Leung Ho YU
-
Publication number: 20120302547Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I) wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.Type: ApplicationFiled: August 8, 2012Publication date: November 29, 2012Applicant: ELI LILLY AND COMPANYInventors: Macklin Brian Arnold, Yen Dao, Kevin Matthew Gardinier, David Joseph Garmene, Steven James Green, Erik James Hembre, Jianliang Lu
-
Patent number: 8299061Abstract: This invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof; as well as a method for treating obesity, a method for treating diabetes, and a pharmaceutical composition.Type: GrantFiled: December 7, 2010Date of Patent: October 30, 2012Assignee: Eli Lilly and CompanyInventors: Macklin Brian Arnold, Thomas James Beauchamp, Emily Jane Canada, Erik James Hembre, Jianliang Lu, John Robert Rizzo, John Mehnert Schaus, Qing Shi
-
Patent number: 8263772Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (1): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.Type: GrantFiled: June 8, 2007Date of Patent: September 11, 2012Assignee: Eli Lilly and CompanyInventors: Macklin Brian Arnold, Yen Dao, Kevin Matthew Gardinier, David Joseph Garmene, Steven James Green, Erik James Hembre, Jianliang Lu
-
Patent number: 8101764Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.Type: GrantFiled: June 8, 2007Date of Patent: January 24, 2012Assignee: Eli Lilly and CompanyInventors: Albert Kudzovi Amegadzie, Yen Dao, Kevin Matthew Gardinier, David Joseph Garmene, Steven James Green, Erik James Hembre, Jianliang Lu, Patrick Gianpietro Spinazze
-
Publication number: 20110144091Abstract: This invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof; as well as a method for treating obesity, a method for treating diabetes, and a pharmaceutical composition.Type: ApplicationFiled: December 7, 2010Publication date: June 16, 2011Applicant: ELI LILLY AND COMPANYInventors: Macklin Brian Arnold, Thomas James Beauchamp, Emily Jane Canada, Erik James Hembre, Jianliang Lu, John Robert Rizzo, John Mehnert Schaus, Qing Shi
-
Patent number: 7897789Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: GrantFiled: July 6, 2009Date of Patent: March 1, 2011Assignee: Eli Lilly and CompanyInventors: Jianliang Lu, Tainwei Ma, Sunil Nagpal, Quanrong Shen, Alan M. Warshawsky, Ying Kwong Yee, Michael John Rupp
-
Patent number: 7772425Abstract: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: GrantFiled: May 22, 2009Date of Patent: August 10, 2010Assignee: Eli Lilly and CompanyInventors: Emilio Enrique Bunel, Robert Peter Gajewski, Charles David Jones, Jianliang Lu, Tianwei Ma, Sunil Nagpal, Ying Kwong Yee
-
Patent number: 7750184Abstract: The present invention relates to novel, non-secosteroidal, sulfonate and sulfonamide functional diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: GrantFiled: November 8, 2004Date of Patent: July 6, 2010Assignee: Eli Lilly and CompanyInventors: Robert Peter Gajewski, Charles David Jones, Jared Harris Linebarger, Jianliang Lu, Tianwei Ma, Sunil Nagpal, Ying Kwong Yee
-
Publication number: 20100076065Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: ApplicationFiled: July 6, 2009Publication date: March 25, 2010Inventors: Jianliang Lu, Tainwei Ma, Sunil Nagpal, Quanrong Shen, Alan M. Warshawsky, Ying Kwong Yee, Michael John Rupp
-
Patent number: 7612067Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.Type: GrantFiled: March 20, 2006Date of Patent: November 3, 2009Assignee: Eli Lilly and CompanyInventors: Heather Janelle Barbosa, Elizabeth Aaron Collins, Chafiq Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Richard Duane Johnston, Jianliang Lu, Michael John Rupp, Takako Takakuwa, Richard Craig Thompson
-
Patent number: 7601850Abstract: The present invention relates to novel, non-secosteroidal, phenyl-thiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: GrantFiled: May 22, 2003Date of Patent: October 13, 2009Assignee: Eli Lilly and CompanyInventors: Karl Robert Dahnke, Robert Peter Gajewski, Charles David Jones, Jared Harris Linebarger, Jianliang Lu, Tianwei Ma, Sunil Nagpal, Todd Parker Simard, Ying Kwong Yee, Emilio Enrique Bunel, Ryan Edward Stites
-
Patent number: 7595345Abstract: The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon-linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: GrantFiled: November 16, 2004Date of Patent: September 29, 2009Assignee: Eli Lilly and CompanyInventors: Emilio Enrique Bunel, Robert Peter Gajewski, Charles David Jones, Jianliang Lu, Sunil Nagpal, Tianwei Ma, Ying Kwong Yee
-
Publication number: 20090227604Abstract: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1a,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: ApplicationFiled: May 22, 2009Publication date: September 10, 2009Inventors: Emilio Enrique Bunel, Robert Peter Gajewski, Charles David Jones, Jianliang Lu, Tianwei Ma, Sunil Nagpal, Ying Kwong Yee
-
Patent number: 7582775Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: GrantFiled: November 16, 2004Date of Patent: September 1, 2009Assignee: Eli Lilly and CompanyInventors: Jianliang Lu, Tainwei Ma, Sunil Nagpal, Quanrong Shen, Alan M. Warshawsky, Ying Kwong Yee, Michael John Rupp
-
Patent number: 7579488Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzofuran compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: GrantFiled: November 16, 2004Date of Patent: August 25, 2009Assignee: Eli Lilly and CompanyInventors: Jianliang Lu, Tianwei Ma, Sunil Nagpal, Quanrong Shen, Alan M. Warshawsky, Jason Matthew Ochoada, Ying Kwong Yee
-
Patent number: 7566803Abstract: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: GrantFiled: November 20, 2003Date of Patent: July 28, 2009Assignee: Eli Lilly and CompanyInventor: Jianliang Lu